Get the Stockscreener App
4.41
8.70%
-0.42
Pre-market:
4.41
Quantum Biopharma Ltd stock is traded at $4.41, with a volume of 1.15M.
It is down -8.70% in the last 24 hours and up +24.23% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$4.83
Open:
$5.08
24h Volume:
1.15M
Relative Volume:
4.29
Market Cap:
$25.71M
Revenue:
-
Net Income/Loss:
$-26.96M
P/E Ratio:
-0.5065
EPS:
-8.7061
Net Cash Flow:
$-8.25M
1W Performance:
+1.38%
1M Performance:
+24.23%
6M Performance:
-46.64%
1Y Performance:
+10.39%
1-Day Range:
$4.40
$6.21
1-Week Range:
$3.51
$6.47
52-Week Range:
$2.07
$19.12
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
4.41 | 25.71M | 0 | -26.96M | -8.25M | -8.7061 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma (QNTM) Files FDA Application for New MS Drug - GuruFocus
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks
Quantum BioPharma submits investigational new drug (IND) application to United States Food and Drug Administration (FDA) - MarketScreener
Quantum BioPharma submits IND application for MS drug candidate - Investing.com
Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan
Quantum BioPharma pushes MS drug toward Phase 2 with FDA filing - Stock Titan
Top Cannabis Stocks To Keep An Eye OnMarch 31st - MarketBeat
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclero - GuruFocus
Quantum BioPharma (QNTM) Partners with Allucent for Lucid-MS Pha - GuruFocus
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclerosis Treatment - gurufocus.com
Quantum BioPharma signs binding letter of intent with Allucent to conduct Phase 2 clinical trial in Multiple Sclerosis - MarketScreener
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - tipranks.com
Quantum BioPharma And Allucent Enter Binding Letter Of Intent For Phase 2 Clinical Trial In Multiple Sclerosis - MarketScreener
Quantum BioPharma partners with Allucent for MS drug trial By Investing.com - Investing.com Australia
Quantum BioPharma Partners with Allucent to Advance Phase 2 Clinical Trial of Lucid-MS for Multiple Sclerosis Treatment - Quiver Quantitative
Quantum BioPharma (QNTM) lines up Allucent for Lucid-MS Phase 2 trial - Stock Titan
New MS treatment targeting demyelination moves toward Phase 2 - Stock Titan
Portfolio Recap: Will Quantum BioPharma Ltd stock benefit from M A2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push - TipRanks
Institution Moves: Will Quantum BioPharma Ltd outperform during market rallies - baoquankhu1.vn
Promising Cannabis Stocks To Add to Your WatchlistMarch 28th - MarketBeat
Can Quantum BioPharma Ltd generate free cash flow2026 Sector Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Quantum Biopharma Provides Corporate Update - Sahm
Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs - TipRanks
Top Cannabis Stocks To Watch TodayMarch 27th - MarketBeat
Quantum BioPharma reports $11.3M cash, runway to January 2028 By Investing.com - Investing.com Canada
Quantum Biopharma Maintains No Going Concern Status in Audited Financial Results for Fiscal Year 2025 - geneonline.com
Quantum BioPharma reports $11.3M cash, runway to January 2028 - Investing.com
Quantum BioPharma Ltd. Completes Phase 1 Trial for MS Drug Lucid-21-302 and Publishes unbuzzd™ Clinical Trial Results - Quiver Quantitative
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status - MarketScreener
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma names principal investigator for MS trial By Investing.com - Investing.com Australia
Quantum BioPharma (FRA:0K91) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - GuruFocus
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Balance Sheet – HAM:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B - TradingView
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status - Bitget
Quantum BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Quantum BioPharma (Nasdaq: QNTM) outlines 2025 drug-development and IP risks - Stock Titan
Diluted earnings per share (diluted EPS) of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAM:0K91 - TradingView
Cannabis Stocks To ResearchMarch 26th - MarketBeat
Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS - TipRanks
Quantum BioPharma announces appointment of principal investigator for planned phase 2 clinical trial of Lucid-21-302 (Lucid-MS) in multiple sclerosis - MarketScreener
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis - The Manila Times
Quantum BioPharma (QNTM) advances Lucid-MS plan, details unbuzzd™ royalties and tax assets - Stock Titan
Quantum Biopharma Announces Appointment of Principal - GlobeNewswire
Best Cannabis Stocks To Watch NowMarch 25th - MarketBeat
Market Outlook: Should I hold or sell Quantum BioPharma Ltd now2026 Setups & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Cannabis Stocks To Add to Your WatchlistMarch 24th - MarketBeat
Quantum BioPharma publishes study on alcohol supplement unbuzzd By Investing.com - Investing.com Australia
Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for Unbuzzd - MarketScreener
Quantum BioPharma publishes study on alcohol supplement unbuzzd - Investing.com
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):